Real–world Experience with JAK Inhibitors and Dupilumab in Dystrophic Epidermolysis Bullosa: A Case Report and Literature Review
DOI:
https://doi.org/10.2340/actadv.v105.43588Keywords:
dystrophic epidermolysis bullosa, JAK inhibitors, DupilumabDownloads
References
Papanikolaou M, Onoufriadis A, Mellerio JE, Nattkemper LA, Yosipovitch G, Steinhoff M, et al. Prevalence, pathophysiology and management of itch in epidermolysis bullosa. Br J Dermatol 2021; 184: 816–825.
https://doi.org/10.1111/bjd.19496 DOI: https://doi.org/10.1111/bjd.19496
Snauwaert JJ, Yuen WY, Jonkman MF, Moons P, Naulaers G, Morren MA. Burden of itch in epidermolysis bullosa. Br J Dermatol 2014; 171: 73–78.
https://doi.org/10.1111/bjd.12885 DOI: https://doi.org/10.1111/bjd.12885
Aala WJF, Hou PC, Hong YK, Lin YC, Lee YR, Tu WT, et al. Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ T helper 2 cells which may contribute to pruritus in lesional skin. Br J
Dermatol 2024; 191: 252–260.
https://doi.org/10.1093/bjd/ljae110 DOI: https://doi.org/10.1093/bjd/ljae110
Hou PC, Aala W Jr, Tu WT, McGrath JA, Hsu CK. Real-world experience of using dupilumab and JAK inhibitors to
manage pruritus in epidermolysis bullosa pruriginosa.
Skin Health Dis 2024; 4: e445.
https://doi.org/10.1002/ski2.445 DOI: https://doi.org/10.1002/ski2.445
Kwon IJ, Kim SE, Kim SC, Lee SE. Efficacy of oral JAK1 or JAK1/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: a retrospective case series. J Dermatol 2024; 51: 441–447.
https://doi.org/10.1111/1346-8138.17079 DOI: https://doi.org/10.1111/1346-8138.17079
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Shihua Ling, Xia Dou
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
